These S&P500 stocks are gapping in today's session

Argus has downgraded Illumina (ILMN) to hold from buy citing falling margins and worsening outlook.

Outlays from the National Institutes of Health ((NIH)) for December 2022 decreased ~4% Y/Y (-35% versus November 2022), according to report from Baird Equity Research.December 2022...

Sharp Tesla price cuts and some notable earnings were in focus.

Illumina may have to pay a fine of 10% of its annual turnover to the EU as a penalty for closing its 2021 acquisition of GRAIL without receiving antitrust clearance,, Reuters reported.

U.S. life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its takeover of Grail without waiting for EU antitrust approval, people familiar with the matter said. Last month Illumina defended its case before senior European Commission and national competition officials at a closed hearing but failed to convince them, the people said. Illumina, which last year set aside $453 million for a potential EU fine, said it would appeal against any fine.

U.S. life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its takeover of Grail without waiting for EU antitrust approval, people familiar with the matter said.

Illumina (ILMN) closed down 6% on Tuesday after its 2023 outlook came in below expectations.

CARLSBAD, Calif. - Jan. 10, 2023 - PRLog -- Universal Sequencing Technology Corporation (UST) announces today, January 10th, 2022, that it has partnered with TATAA Biocenter, one of our key distributors in Europe, to offer full-service solutions for Long Read Sequencing Applications using UST TELL-Seq Linked Read technology.TATAA Biocenter was founded in 2001 and is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industries in Europe and to the Cell and Gene Therapy industry in the United States.UST's TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2nd generation NGS platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb, up to and exceeding 200kb). A sequencing-ready library can be prepared in a PCR tube in ~3 hours with a simple workflow and basic lab equipment, which is simple, fast, and cost-effective. A unique feature of UST TELL-Seq is that it only requires ultra-low DNA input, 3-5ng for the human genome and 0.1-0.5ng for microbial genomes and target sequencing panels.Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, who recently visited the TATAA Biocenter facility in Gothenburg, stated that he was impressed with the laboratory's setup, corporate culture, professionalism, and up-to-code superb sequencing services. Levy added that "TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and TATAA, based on the growing need for long-read results with very accurate short-read Illumina sequencers is speeding up the adoption of UST's super long-range TELL-Seq NGS library products among Illumina users in the US and all over the world."With UST TELL-Seq library preparation kits and an Illumina sequencer, one can do de novo sequencing of microbial, animal, plant, and insect genomes, metagenomics, human genome phasing, and structural variation detection.Mikael Kubista, the founder and CEO of TATAA Biocenter, stated, "The innovative TELL-Seq Linked-Read Technology for long-read sequencing is a most welcome complement to our service offerings. Our customers and sponsors will now gain additional advantages over their competitors through our broad range of qualified molecular services."ABOUT TATAA BIOCENTERTATAA Biocenter is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and to the Cell and Gene Therapy industry in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices(GLP/GCP) ready facility TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling, including genomics, transcriptomics, and proteomics with traditional qPCR, dPCR, and NGS methods, as well as proprietary methods.ABOUT UNIVERSAL SEQUENCING TECHNOLOGY CORPORATIONUniversal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.www.universalsequencing.com